Skip to main content

QIAGEN’s Eco-Friendlier Products Earn Prestigious ACT Label

  • QIAwave products showed 35% lower environmental impact
  • First in industry to receive ACT label for sample preparation kits
  • QIAGEN and My Green Lab to collaborate on laboratory sustainability efforts

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its recently launched, environmentally friendlier QIAwave nucleic-acid extraction kits have received the prestigious ACT Environmental Impact Factor Label from My Green Lab, a non-profit organization dedicated to advancing sustainability in scientific research.

In awarding the ACT (Accountability, Consistency, and Transparency) labels, My Green Lab found that the three QIAwave products had a 35% improved Environmental Impact Factor when compared to QIAGEN’s standard kits, taking into account such criteria as, manufacturing impact reduction, responsible chemical management, product and packaging content as well as disposal of packaging.

QIAGEN launched the QIAwave portfolio in January with the QIAwave RNA Mini Kit, QIAwave DNA Blood & Tissue Kit and QIAwave Plasmid Miniprep Kit. All are designed to use fewer components and produce less waste, and are the first such kits to use both recycled plastics and space-saving chemical concentrates. They represent the first wave of QIAGEN’s sustainability-driven product innovations and a major step in reducing the environmental impact of the company’s overall portfolio.

To date, My Green Lab has awarded the ACT label to more than 4,000 products across the global life sciences industry, with QIAGEN’s products the first nucleic-acid extraction kits to receive this stamp of approval from the respected independent arbiter. Going forward, QIAGEN will closely collaborate with the California-based organization to advance its Green Lab Certification Program, which aims to increase transparency around the environmental impact of research laboratories, and work toward certification of QIAGEN’s own research and development labs.

"My Green Lab puts the spotlight on companies to meet head-on the immense ecological challenges facing planet Earth," said Thomas Schweins, Senior Vice President and Head of QIAGEN’s Life Science Business Area. "We at QIAGEN take that challenge very seriously. Today’s recognition of our eco-friendlier kits is another proof-point of our commitment to sustainability and an important milestone in our campaign to significantly reduce the environmental impact of our entire product range."

QIAGEN aims to reduce plastic packaging waste by a further 9% in 2022, following a 9.6% reduction achieved in 2021. The company’s Plastic Footprint Task Force, founded in 2018, manages initiatives such as replacing expanded-polystyrene boxes for cooled shipments with recyclable alternatives. Beyond reducing its plastic footprint, QIAGEN has pledged to cut carbon emissions in line with the goal of reaching the Science Based Targets Net-Zero Standard by 2050, and constantly monitors its global environmental impact, economic influence and corporate citizenship. The sustainability agency ISS ESG has given QIAGEN its highest “Prime” rating.

More information about QIAwave ACT labels can be found here.

More information about QIAGEN’s vision of a sustainable future can be found here.


QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of March 31, 2022, QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Source: QIAGEN N.V.

Category: Corporate



Investor Relations

John Gilardi, +49 2103 29 11711

Phoebe Loh, +49 2103 29 11457

Public Relations

Thomas Theuringer, +49 2103 29 11826

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.